Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine added to basal immunotherapy for lupus nephritis with heavy proteinuria
ChiCTR-TRC-13004257Phase 4Completed
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hydroxychloroquine in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (2 arms), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoints: Neutrophil gelatinase-associated lipocalin, Interleukin-18 and 2 more. Started Jun 2013; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on ChiCTR-TRC-13004257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13004257.